In the past decade, Creative Biolabs practices and has gained rich experience in antibody discovery, engineering, in vitro evaluation, in vivo assessment, etc. Now we are hoping to extend our experience on Next-IO™ programs, with a hope to co-develop the therapeutic antibody drug pipelines with trustful partners. We are dedicated to forwarding the progress to the pre-IND stage in an effective manner. This program aims to develop the therapeutic monoclonal antibody (mAb), specifically, against cadherin.
Cadherin is a family of critical adhesion molecules involving in cell-cell adhesion, junction formation, and tissue morphogenesis. There are several members in the family, to name, E-cadherin, N-cadherin, and R-cadherin. In epithelial cells, E-cadherin is essential for cell-cell interaction maintenance and maintaining the balance of polarized epithelial monolayers. E-cadherin is the important ligand for KLRG1, a critical immune checkpoint expressed on NK cells (see Fig.1). Their interaction promotes tumor progression. Studies also indicatedthe98 loss of E-cadherin function is strongly associated with cancer progression.
Among all the cancer types that experience the loss of E-cadherin expression, it’s demonstrated that activating monoclonal antibody against E-cadherin can significantly decrease the lung metastasis. Another study indicated that soluble E-cadherin is highly expressed in ovarian cancer patients and may be correlated with angiogenesis. These data imply E-cadherin has the potential to become a therapeutic target in cancer treatments. In addition, N-cadherin, another member of cadherin, is highly expressed in colorectal cancer (CRC), which suggests its potential therapeutic role in treating CRC. In summary, cadherin relates to tumor invasion, metastasis, and tumorigenesis, and targeting cadherins may be a promising approach to inhibit tumor progression.
Our anti-Cadherin mAb program aims to develop the novel therapeutic mAb against different Cadherin members for cancer treatment. We propose three following pathways for your choice.
Except for monoclonal antibody, we also focus on combination strategies, or other antibody modalities, such as bispecific antibody, etc. to cover the full spectrum of cancer immunotherapies targeting cadherins. If you have interests, please feel free to reach out to our scientists for further consultation.
Based on these data, N-cadherin is shown to be a potential target to treat CRC and blocking N-cadherin (alone or in combination with other treatments) maybe a promising immunotherapeutic strategy to treat CRC.
We have extensive experience in performing comprehensive program developments and effective problem-solving. For our Next-IO™ programs, we are committed to delivering the program to the pre-IND stage within about 1.5 years. Accurate timeline will be determined on a case-by-case basis. Here is a draft timeline for your glance.
Fig.1 The timeline of Next-IOᵀᴹ programs.
Creative Biolabs is seeking potential partners to co-develop the cancer immunotherapies targeting different members of cadherins. Equipped with state-of-the-art facilities, our team is dedicated to providing end-to-end drug discovery and development programs. Our unique Next-IO™ programs will surely unleash the creative spirit and achieve significant success in the field of immuno-oncology. Please contact us to learn how we can collaborate further.
For Research Use Only | Not For Clinical Use
Download our brochure